A new study by the Stony Brook University indicates that fructose consumption may actually aggravate an intestinal inflammation into inflammatory bowel disease. The study, which was led by David Montrose of the Stony Brook University Renaissance School of Medicine, was published in the Cellular and Molecular Gastroenterology and Hepatology online journal.
According to the U.S. CDC, roughly three million Americans are diagnosed with Inflammatory Bowel Diseases (“IBD”) each year, which is a one million increase in the number of cases in comparison with cases in the late 90s. The number of IBD cases appears to be increasing globally as well. The consumption of a Western diet, which includes fructose, has been shown to increase the risk of diabetes and obesity. Now, it turns out Inflammatory Bowel Diseases may also be worsened by the consumption of fructose.
Montrose, who is a faculty researcher in the Cancer Center at Stony Brook University as well as an assistant professor in the Pathology department, says that the increase in the number of IBD cases corresponds with the higher fructose consumption levels in the U.S. and other nations.
The research findings indicate a dietary connection between IBD and fructose. This supports the theory that a high fructose consumption will exacerbate the ailment for people with IBD. These results, he adds, are important as they can be used to give guidance on the alternative dietary choices for individuals who have IBD.
Together with his colleagues at the Weill Cornell Medicine, Montrose ran tests using 3 IBD mouse models. They observed that feeding the mice with high fructose amounts aggravated colonic inflammation with changes in their gut bacteria metabolism, type and localization in the colon. Corresponding mechanistic work showed that the microbiota in the gut was linked to the cause of the harmful effect of the high fructose diet.
The study states in its conclusion that the consumption of dietary fructose in excess had an inflammatory effect on the colon, which could be explained by the changes in distribution, composition and metabolic function of the colonic microbiota.
Montrose reveals that the research’s next steps are to learn more about these findings, and explore further. This includes the evaluation of whether the fructose diet grows colitis-associated tumorigenesis. This is extremely important as many people with IBD have an increased risk of developing colon cancer because of the chronic inflammation of their gut for a huge part of their lives. Biotech companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could use these research findings to develop some life-saving interventions for people with inflammatory bowel disease in the future.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
